-

01:33:13 PM

INCY Stock News

INCY - Incyte Corp.

03/29/21 12:04 PM

Nasdaq : INCY

Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Pemazyre ® (pemigatinib) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at

RHEA-AI

neutral

03/23/21 5:13 AM

Nasdaq : INCY

Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy

Incyte (Nasdaq:INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre ® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast

RHEA-AI

positive

03/18/21 4:30 PM

Nasdaq : INCY

clinical trialcovid-19

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Incyte (Nasdaq:INCY) today announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients on mechanical ventilation with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS), a type of

RHEA-AI

neutral

03/11/21 8:00 AM

Nasdaq : INCY

Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.“At AACR 2021, we look forward to sharing

RHEA-AI

neutral

03/03/21 6:45 AM

Nasdaq, NYSE : INCY, LLY

clinical trial

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). Both doses

RHEA-AI

negative

02/26/21 3:00 AM

Nasdaq : INCY

Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)

Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on,

RHEA-AI

neutral

02/22/21 8:00 AM

Nasdaq : INCY

Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (ruxolitinib) as a Treatment for Patients with Chronic Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi ®) for treatment of steroid-refractory chronic graft-versus-host disease (GVHD) in adult and pediatric patients

RHEA-AI

neutral

02/19/21 8:00 AM

Nasdaq : INCY

Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, as a treatment for atopic dermatitis (AD), a type of

RHEA-AI

neutral

02/11/21 8:00 AM

Nasdaq : INCY

conferences

Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the virtual Cowen 41 st Annual Health Care Conference on Wednesday, March 3, 2021 at 2:00 p.m. EST.The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 90 days.About

RHEA-AI

neutral

02/09/21 7:00 AM

Nasdaq : INCY

earnings

Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs

Incyte (Nasdaq: INCY) today reports 2020 fourth quarter and full year financial results, and provides a status update on the Company’s development portfolio.“Our team achieved many important accomplishments in the past year. Revenue growth was strong, driven by demand for Jakafi ® (ruxolitinib),

RHEA-AI

very positive

Prev 1 2 3 4 5 6 7 8 9 Next